Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Clinical Immunology · Chronic Mucocutaneous Candidiasis

The Diagnostic Path: Finding the Root Cause of CMC

At a Glance

Chronic mucocutaneous candidiasis can be present even when routine blood counts and antibody tests are normal. Finding its cause may require specialized immune-function tests, genetic testing, and Candida culture with antifungal susceptibility testing to guide care.

The journey to a diagnosis of Chronic Mucocutaneous Candidiasis (CMC) often begins with a paradox: you feel unwell and have visible, persistent infections, yet your standard blood tests keep coming back “normal.” This is common in CMC because the immune defects are often highly specialized, affecting only the specific “security channel” used to fight fungus while leaving the rest of the immune system appearing healthy [1][2].

Moving beyond basic screening to specialized immunology is the key to unlocking the right treatment plan.

Why Standard Blood Tests Aren’t Enough

Most patients start with a Complete Blood Count (CBC) or a quantitative immunoglobulin test. While these are important for ruling out other major immune failures, they rarely provide an answer for CMC [3].

  • The “Normal” Trap: In many forms of CMC, your total white blood cell counts, antibody levels, and vaccine responses are perfectly normal [4][2].
  • The Specialist Shift: Because the defect is often tucked away inside how cells signal to one another (the IL-17 pathway), doctors must use “functional” tests that challenge your cells to see if they can perform their specific anti-fungal duties [5][6].

Functional Immune Testing: Testing the “Wiring”

Once a doctor suspects CMC, they may use specialized laboratory techniques to look at how your immune cells behave. A normal result does not exclude CMC.

  • Th17 Flow Cytometry: This test counts the number of “commander” cells (Th17 cells) in your blood [7]. A low count is a clue for many types of CMC, including STAT1-GOF [8].
  • Candida Stimulation Assays: In this test, your blood is exposed to Candida in a lab dish to see if it produces the necessary defense signals (like IL-17A and IL-22) [9][10].
  • STAT1 Phosphorylation: For patients suspected of having an overactive immune pathway, this test measures how quickly your cells react to signals. In STAT1 Gain-of-Function, the reaction is often too strong or lasts too long [8][11].

Genetic Panels: The Definitive Map

Because CMC can be caused by many different genetic “typos,” a targeted genetic panel is a key tool for diagnosis [6][12]. A variant of uncertain significance (VUS) is not diagnostic alone, and genetic counseling is recommended. A complete CMC panel may examine several specific genes:

  • STAT1: The most common known cause of syndromic CMC [13].
  • AIRE: The gene responsible for APECED/APS-1 [14].
  • IL17RA, IL17RC, and IL17F: Genes that control the “receivers” and “signals” for fungal defense [13].
  • CARD9: A critical gene for protecting against invasive, deep-tissue fungal infections [15].

Mycology: Identifying the Enemy

It is not enough to know you have a yeast infection; your team needs to know exactly which yeast it is and what kills it. Cultures from mucous membranes can sometimes represent harmless colonization.

  • Species Identification: While Candida albicans is most common, other species like Candida parapsilosis can also be involved [16][17].
  • Susceptibility (MIC) Testing: This is one of the most critical tests for CMC patients. Because you may need long-term antifungal therapy, the yeast can become resistant to standard drugs like fluconazole [18][19]. Minimum Inhibitory Concentration (MIC) testing is interpreted with laboratory breakpoints to help guide drug and dose selection [20].

Diagnostic Options Checklist

These are tests your care team may consider to ensure your evaluation has covered all the necessary bases for a long-term care plan:

  • [ ] Microbiologic Confirmation: Has the fungus been cultured and identified by species? [16]
  • [ ] Susceptibility Profile: Do you have a recent report showing which antifungals the yeast is sensitive to? [18]
  • [ ] Functional Th17 Assay: Have your Th17 cell levels been measured? [7]
  • [ ] Targeted Genetic Panel: Has a panel covering STAT1, AIRE, IL-17, and CARD9 been completed? [13]
  • [ ] Syndromic Baseline: If a syndromic cause (like STAT1-GOF or APECED) is suspected, have you had baseline checks for:
    • Thyroid and adrenal function? [21]
    • Calcium and vitamin D levels? [22]
    • Lung health (if chronic cough is present)? [23]
  • [ ] Secondary Review: Has your team ruled out other factors like diabetes or medication side effects that could be making the infections worse? [24][6]

Common questions in this guide

Can I have CMC if my CBC and basic immune tests are normal?
Yes. CMC can result from a narrowly focused problem in antifungal immune signaling, especially the IL-17 pathway, while total white-cell counts, antibody levels, and vaccine responses remain normal. Normal screening tests therefore do not by themselves rule out CMC.
Which specialized tests can help find the cause of CMC?
Clinicians may use Th17 flow cytometry, Candida stimulation assays that measure IL-17A and IL-22 responses, and STAT1 phosphorylation testing. A targeted genetic panel and fungal culture can add information about inherited immune defects and the infecting yeast.
What genes are included in a genetic panel for CMC?
Panels may include STAT1, AIRE, IL17RA, IL17RC, IL17F, and CARD9, among other genes. A variant of uncertain significance does not prove that a gene change causes CMC, so clinicians may combine the result with clinical findings and functional testing, with genetic counseling recommended.
Why are Candida culture and MIC testing important?
A culture can identify the Candida species and distinguish an infection from possible harmless colonization. MIC testing measures how much of an antifungal is needed to inhibit the yeast and helps clinicians choose a drug and dose, especially when long-term treatment may lead to resistance.
What baseline health checks may be needed if a syndromic cause is suspected?
Depending on the suspected cause, clinicians may check thyroid and adrenal function, calcium and vitamin D, and lung health when a chronic cough is present. They may also review diabetes and medication effects that could worsen fungal infections.
What does it mean if my CMC genetic test finds a variant of uncertain significance?
A variant of uncertain significance is not diagnostic on its own and should not be treated as proof of a cause. Your care team may compare it with your symptoms and use functional immune testing and genetic counseling to decide whether it could be relevant.
Does a normal Th17 or other functional test rule out CMC?
No. CMC can result from different immune pathway defects, so a normal result on one functional assay does not exclude it. Clinicians interpret the test alongside symptoms, cultures, genetic findings, and other immune studies.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on chronic mucocutaneous candidiasis due to lymphokine deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since my CBC and basic immune panels look normal, which specialized functional tests (like Th17 flow cytometry) will we use to pinpoint the defect?
  2. 2.Can we perform fungal susceptibility (MIC) testing on my current infection to ensure the medication we are using is still effective?
  3. 3.Does my genetic panel include looking for 'gain-of-function' mutations in STAT1 or autoantibodies related to APECED?
  4. 4.Should we establish baseline hormone and organ function tests now, even if my only current symptoms are fungal infections?
  5. 5.If my genetic results show a 'variant of uncertain significance,' how will we use functional testing to determine if it is the cause of my CMC?

References

References (24)
  1. 1

    A gain-of-function mutation of STAT1: A novel genetic factor contributing to chronic mucocutaneous candidiasis.

    Eslami N, Tavakol M, Mesdaghi M, et al.

    Acta microbiologica et immunologica Hungarica 2017; (64(2)):191-201 doi:10.1556/030.64.2017.014.

    PMID: 28597685
  2. 2

    Chronic Mucocutaneous Candidiasis in an Adolescent Boy Due to a Novel Mutation in TRAF3IP2.

    Bhattad S, Dinakar C, Pinnamaraju H, et al.

    Journal of clinical immunology 2019; (39(6)):596-599 doi:10.1007/s10875-019-00664-x.

    PMID: 31292894
  3. 3

    Inborn Error of Immunity or Atopic Dermatitis: When to be Concerned and How to Investigate.

    Stadler PC, Renner ED, Milner J, Wollenberg A

    The journal of allergy and clinical immunology. In practice 2021; (9(4)):1501-1507 doi:10.1016/j.jaip.2021.01.037.

    PMID: 33548520
  4. 4

    Disseminated Tuberculosis and Early-Onset SLE in a Child with a Novel STAT1 Gain-of-Function Mutation: a Case Report.

    Arslan S, Sert A, Özçelik M, et al.

    Journal of clinical immunology 2026; (46(1)).

    PMID: 42319627
  5. 5

    Immunologic characterization of patients with chronic mucocutaneous candidiasis disease.

    Khalsa KK, Yang Q, Shen X, et al.

    Clinical case reports 2019; (7(1)):180-185 doi:10.1002/ccr3.1946.

    PMID: 30656037
  6. 6

    Chronic Candidiasis in Children.

    Green L, Dolen WK

    Current allergy and asthma reports 2017; (17(5)):31 doi:10.1007/s11882-017-0699-9.

    PMID: 28429308
  7. 7

    From Validation to Clinical Interpretation: A Flow Cytometric Th17-Cell Assay for STAT1- and STAT3-Related Inborn Errors of Immunity.

    Toft MJ, Sørensen CD, Christiansen M, et al.

    Scandinavian journal of immunology 2026; (104(2)):e70140 doi:10.1111/sji.70140.

    PMID: 42596513
  8. 8

    The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.

    Depner M, Fuchs S, Raabe J, et al.

    Journal of clinical immunology 2016; (36(1)):73-84 doi:10.1007/s10875-015-0214-9.

    PMID: 26604104
  9. 9

    Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel STAT1 Gain-of-Function Mutation.

    Erdős M, Jakobicz E, Soltész B, et al.

    Frontiers in immunology 2020; (11()):967 doi:10.3389/fimmu.2020.00967.

    PMID: 32547544
  10. 10

    Altered Immune Activation and IL-23 Signaling in Response to Candida albicans in Autoimmune Polyendocrine Syndrome Type 1.

    Bruserud Ø, Bratland E, Hellesen A, et al.

    Frontiers in immunology 2017; (8()):1074 doi:10.3389/fimmu.2017.01074.

    PMID: 28919897
  11. 11

    Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.

    Kayaoglu B, Kasap N, Yilmaz NS, et al.

    Journal of clinical immunology 2021; (41(4)):769-779 doi:10.1007/s10875-020-00943-y.

    PMID: 33475942
  12. 12

    Chronic mucocutaneous candidiasis.

    Hon-Balla B, Erdős M

    Orvosi hetilap 2022; (163(5)):171-180 doi:10.1556/650.2022.32409.

    PMID: 35093925
  13. 13

    Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity.

    Okada S, Puel A, Casanova JL, Kobayashi M

    Clinical & translational immunology 2016; (5(12)):e114 doi:10.1038/cti.2016.71.

    PMID: 28090315
  14. 14

    The Evolving View of IL-17-Mediated Immunity in Defense Against Mucocutaneous Candidiasis in Humans.

    Soltész B, Tóth B, Sarkadi AK, et al.

    International reviews of immunology 2015; (34(4)):348-63 doi:10.3109/08830185.2015.1049345.

    PMID: 26154078
  15. 15

    Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency.

    Alves de Medeiros AK, Lodewick E, Bogaert DJ, et al.

    Journal of clinical immunology 2016; (36(3)):204-9 doi:10.1007/s10875-016-0255-8.

    PMID: 26961233
  16. 16

    Chronic Mucocutaneous Candidiasis: A Case Report.

    Wang Z, Zhang Y, Ma W

    Clinical, cosmetic and investigational dermatology 2023; (16()):231-236 doi:10.2147/CCID.S396802.

    PMID: 36721837
  17. 17

    Recurrent Enteritis and Intestinal Obstruction in a Patient with Chronic Mucocutaneous Candidiasis due to STAT1 Gain-of-Function Mutation.

    Luo M, Huang H, Nie H, et al.

    Mycopathologia 2024; (190(1)):3 doi:10.1007/s11046-024-00912-8.

    PMID: 39707011
  18. 18

    Persistence of Clonal Azole-Resistant Isolates of Candida albicans from a Patient with Chronic Mucocutaneous Candidiasis in Colombia.

    Ceballos-Garzon A, Wintaco-Martínez LM, Velez N, et al.

    Journal of global infectious diseases 2020; (12(1)):16-20 doi:10.4103/jgid.jgid_74_19.

    PMID: 32165797
  19. 19

    Molecular mechanism of azoles resistant Candida albicans in a patient with chronic mucocutaneous candidiasis.

    Zhang MR, Zhao F, Wang S, et al.

    BMC infectious diseases 2020; (20(1)):126 doi:10.1186/s12879-020-4856-8.

    PMID: 32046674
  20. 20

    Clonal Strain Persistence of Candida albicans Isolates from Chronic Mucocutaneous Candidiasis Patients.

    Moorhouse AJ, Rennison C, Raza M, et al.

    PloS one 2016; (11(2)):e0145888 doi:10.1371/journal.pone.0145888.

    PMID: 26849050
  21. 21

    Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.

    Ferré EMN, Schmitt MM, Lionakis MS

    Frontiers in pediatrics 2021; (9()):723532 doi:10.3389/fped.2021.723532.

    PMID: 34790633
  22. 22

    Autoimmune polyendocrine syndrome type 1 (APECED) in the Indian population: case report and review of a series of 45 patients.

    Fierabracci A, Arena A, Toto F, et al.

    Journal of endocrinological investigation 2021; (44(4)):661-677 doi:10.1007/s40618-020-01376-5.

    PMID: 32767280
  23. 23

    Chronic Candida infection, bronchiectasis, immunoglobulin abnormalities, and stunting: a case report of a natural mutation of STAT1 (c.986C>G) in an adolescent male.

    Yu Y, Xu F, Shen H, Wu J

    BMC infectious diseases 2021; (21(1)):38 doi:10.1186/s12879-020-05734-9.

    PMID: 33413180
  24. 24

    Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation.

    Koo S, Kejariwal D, Al-Shehri T, et al.

    United European gastroenterology journal 2017; (5(5)):625-631 doi:10.1177/2050640616684404.

    PMID: 28815025

This page is for informational purposes only and does not constitute medical advice. An immunologist or infectious disease clinician should interpret your immune, genetic, and fungal test results in the context of your care.